The Latest Breaking News from LLY

As the battle for dominance heats up in the weight loss market, which stock is a better investment now?

The U.S. pharmaceutical industry is at the center of a policy maelstrom. President Donald Trump on Sep 25, put a 100% tariff on imported branded and patented medicines starting from Oct 1 with threats that tariffs might go up to as much as 250% in future. The instant market impact…

President Donald Trump‘s proposed 100% tariffs on pharmaceuticals could have a smaller impact than initially expected, thanks to certain loopholes. However, the pharmaceutical industry, particularly Big Pharma, remains displeased.

On Thursday, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Co.’s (NYSE: LLY) Inluriyo (imlunestrant) for adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer (MBC) whose disease progressed after at least one line of endocrine therapy (ET).

Eli Lilly and Company (NYSE: LLY) shares are trading lower after the company ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began. The termination is a setback for Lilly’s obesity pipeline among growing investor expectations.

On Wednesday, Eli Lilly Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.

Eli Lilly and Co. (NYSE:LLY) CEO Dave Ricks strongly criticized the United Kingdom's approach to drug pricing, describing it as "probably the worst country in Europe" for pharmaceutical prices.

Eli Lilly stock rises on FDA fast-track hopes for its oral GLP-1 obesity drug and $27B U.S. manufacturing expansion; it's a tough trade but solid long-term hold

The U.S. Food and Drug Administration’s recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question.

Eli Lilly and Co (NYSE:LLY) on Tuesday shared detailed results from the Phase 3 ATTAIN-1 trial, evaluating the safety and efficacy of oral orforglipron in adults with obesity, or overweight with a weight-related medical problem, and without diabetes.

The U.S. Food and Drug Administration (FDA) has determined that a promotional video featuring Zepbound and Mounjaro (tirzepatide), both produced by Eli Lilly And Co. (NYSE:LLY), is false or misleading.